3002.13.00.10/Rituximab Monoclonal Antibody/Canada

Rituximab Monoclonal Antibody from Canada

Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used primarily for treating non-Hodgkin lymphoma and rheumatoid arthritis. It falls under HTS 3002.13.0010 as an unmixed immunological product consisting of monoclonal antibodies obtained via biotechnological processes, not put up in measured doses for retail sale. This classification applies to bulk pharmaceutical-grade preparations for further formulation.

Duty Rate — Canada → United States

0%

Rate breakdown

9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Calculate with your customs valueVerify classification with AI

Import Tips

• Verify FDA import alerts and biologics license applications; monoclonal antibodies require prior approval via IND or BLA

• Ensure cold chain documentation (2-8°C) and Certificate of Analysis confirming purity >95% and biotech origin

• Avoid misclassification as finished injectables; bulk form must not be in measured doses to qualify